PIK3CA and acute lymphoblastic leukemia: To dissect the relative contributions of PI3K and the mTORC1 and mTORC2 complexes, we exposed ALL-LTCs to the allosteric mTORC1 inhibitor RAD001 and the selective panPI3K inhibitor NVP-BKM120, both of which are being evaluated for anti-neoplastic activity in clinical trials.